CDA | Evidence Driven
CDA | Evidence Driven

Revlimid for Multiple Myeloma - Details

Details

Files
Generic Name:
Lenalidomide
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma (as maintenance therapy)
Manufacturer:
Celgene Inc.
Brand Name:
Revlimid
Project Line:
Reimbursement Review
Project Number:
PC0029-000
Performance Metric:
N/A — Predated performance metrics
Strength:
5mg, 10mg, 15mg and 25mg capsules
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
For the maintenance treatment of newly diagnosed multiple myeloma in patients after stem-cell transplantation
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Lenalidomide (Revlimid) for Multiple Myeloma - pERC Final Recommendation Final Recommendation October 22, 2013 View PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Final Clinical Guidance Report Guidance Reports October 22, 2013 View PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Final Economic Guidance Report Guidance Reports October 22, 2013 View PDF
Lenalidomide (Revlimid) for Multiple Myeloma - pERC Initial Recommendation Initial Recommendation October 3, 2013 View PDF
Lenalidomide (Revlimid) for Multiple Myeloma - PAG Feedback on Initial Recommendation Feedback October 22, 2013 View PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Manufacturer (Celgene Inc.) Feedback on Initial Recommendation Feedback October 22, 2013 View PDF
Lenalidomide (Revlimid) for Multiple Myeloma - Patient Advocacy Group (Myeloma Canada) COI Declarations Feedback October 22, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : November 6, 2013